European registry evaluating management practices and pharmacological treatment outcomes in patients with LUTS/BPH.
¡°European LUTS/BPH Registry¡±.

A patient will be considered eligible for inclusion in this registry only if all of the following criteria apply:

1. Males, aged ¡Ã50 years;

2. Patients with LUTS/BPH presenting to the GP or urologist who are either:

A. Presently/recently untreated with pharmacological agents for LUTS/BPH and with an IPSS ¡Ã8 starting LUTS/BPH pharmacological treatment at or directly after the baseline visit, and fulfilling one of the following criteria:

a. Newly diagnosed;

b. Previously managed with watchful waiting;

c. Discontinued LUTS/BPH pharmacological treatment prior to the baseline visit for the following period:

- Blockers or phytotherapy or anticholinergics for ¡Ã 1 month;

- 5ARIs either as monotherapy or in combination for ¡Ã 6 months;

- Other LUTS/BPH medical therapy for ¡Ã1 months;

OR

B. Presently/recently treated with pharmacological agents for LUTS/BPH prior to the baseline visit for the following period, and will continue LUTS/BPH pharmacological treatment:

a. Blockers or phytotherapy or anticholinergics for ¡Ã 1 month;

b. 5ARIs either as monotherapy or in combination for ¡Ã 6 months;

c. Other LUTS/BPH medical therapy for ¡Ã1 months.

3. Patient has given written informed consent to take part in the registry for a period up to 2 years;

4. Patient is capable of understanding and completing the questionnaires.

A patient will not be eligible for inclusion in this registry if any of the following criteria apply:

1. Patients with other pathological or metabolic conditions that might explain the LUTS (e.g. bladder infection, chronic cystitis, bladder/prostate cancer, bladder stones);

2. Patients in whom the decision has been taken at baseline visit to manage them with watchful waiting or other then pharmacological LUTS/BPH therapy;

3. Patients with previous history of prostate cancer;

4. Patients who are participating, or have participated in the last 6 months, in any interventional clinical trial;

5. Patients planning to move to another part of the country or abroad which indicates that they need to discontinue participation prior to the total follow up of 2 years;

6. Patients previously treated with minimal invasive or surgical treatments for their LUTS/BPH or surgical treatments involving the bladder, prostate or urethra;

7. Patients with a history or current illness (including psychiatric) that, in the opinion of the investigator, might confound the results of the registry.